Technical Analysis for IMM - Immupharma Plc

Grade Last Price % Change Price Change
B 6.9 -8.61% -0.65
IMM closed up 2.03 percent on Monday, January 17, 2022, on 24 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical IMM trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish -8.61%
20 DMA Support Bullish -8.61%
1,2,3 Pullback Bullish Bullish Swing Setup -8.61%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.61%
Outside Day Range Expansion -8.61%
Boomer Buy Setup Bullish Swing Setup -6.76%
Narrow Range Bar Range Contraction -6.76%
NR7 Range Contraction -6.76%
NR7-2 Range Contraction -6.76%
Inside Day Range Contraction -6.76%
Older End-of-Day Signals for IMM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 9 hours ago
10 DMA Resistance about 9 hours ago
20 DMA Support about 10 hours ago
2x Volume Pace about 10 hours ago
1.5x Volume Pace about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immupharma Plc Description

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Clinic Cement Disease Earl Cancer Medical Specialties Diseases Drugs Mr Drug Discovery Autoimmune Diseases Disorders Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus

Is IMM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 13.079
52 Week Low 4.8
Average Volume 968,478
200-Day Moving Average 7.89
50-Day Moving Average 6.63
20-Day Moving Average 7.08
10-Day Moving Average 7.37
Average True Range 0.88
ADX 38.86
+DI 21.11
-DI 5.45
Chandelier Exit (Long, 3 ATRs) 5.84
Chandelier Exit (Short, 3 ATRs) 7.94
Upper Bollinger Bands 8.06
Lower Bollinger Band 6.11
Percent B (%b) 0.74
BandWidth 27.58
MACD Line 0.30
MACD Signal Line 0.25
MACD Histogram 0.049
Fundamentals Value
Market Cap 18.89 Million
Num Shares 250 Million
EPS -5.10
Price-to-Earnings (P/E) Ratio -1.48
Price-to-Sales 168.34
Price-to-Book 5.29
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.99
Resistance 3 (R3) 8.97 8.46 8.75
Resistance 2 (R2) 8.46 8.10 8.48 8.67
Resistance 1 (R1) 8.01 7.87 7.76 8.03 8.59
Pivot Point 7.50 7.50 7.38 7.52 7.50
Support 1 (S1) 7.05 7.14 6.80 7.07 6.51
Support 2 (S2) 6.54 6.91 6.56 6.43
Support 3 (S3) 6.09 6.54 6.35
Support 4 (S4) 6.11